Answers are grounded in this paper and cite their sources.
No significant safety issues were observed with LDX 30, 50, or 70 mg/d administered for 1 year in Japanese children and adolescents with ADHD. LDX was associated with long-term reductions in ADHD symptoms and severity.
No takes yet. Share an insight, caveat, or question.
Ichikawa et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: